Application 761344
- Type
- BLA
- Sponsor
- AMGEN INC
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761344 | Imdelltra | tarlatamab-dlle | 351(a) | Rx | 2026-10-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | IMDELLTRA | TARLATAMAB-DLLE | INJECTABLE;INJECTION | 1MG | No | No |
| 002 | IMDELLTRA | TARLATAMAB-DLLE | INJECTABLE;INJECTION | 10MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| IMDELLTRA (AMG757) | TARLATAMAB-DLLE | Amgen, Inc | 1e7b6163-5d83-42ea-82c9-cf7620cdc782 | 2026-09-11 | Boxed warning, Warnings, Adverse reactions | BLA761344 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.